Article
Neutralization of SARS-CoV-2 variants by rVSV-ΔG-spike-elicited human sera
2021-11-24
Abstract excerpt
The emergence of rapidly spreading variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a major challenge to the ability of vaccines and therapeutic antibodies to provide immunity. These variants contain mutations at specific amino acids that might impede vaccine efficacy. BriLife® (rVSV-ΔG-spike) is a newly developed SARS-CoV-2 vaccine candidate currently in Phase II clinical trials. It...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 9915c5c3-d09c-5e16-9345-9e68cc367385
- DOI
- 10.1101/2021.11.22.21266673
